Bone densitometry firm Hologic of Waltham, MA, announced a two-for-onestock split effective March 25. Hologic's share price has risensteadily since last year, when Merck received marketing approvalfor its Fosamax osteoporosis drug, and the split will
Bone densitometry firm Hologic of Waltham, MA, announced a two-for-one
stock split effective March 25. Hologic's share price has risen
steadily since last year, when Merck received marketing approval
for its Fosamax osteoporosis drug, and the split will make the
company's stock more affordable. Hologic's stock was trading at
around $50 a share the week before the split. It had been trading
at around $14 a share last March (SCAN 12/27/95).
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.